在现实环境中,双膦酸盐治疗导致癌症患者住院的高钙血症的治疗结果

IF 0.9 4区 医学 Q4 ONCOLOGY
Tasnim Quran, Nour Maraqa, Joud Aqarbeh, Renad Abu-Khader, Ayah Habeeb, Nour Faqeer
{"title":"在现实环境中,双膦酸盐治疗导致癌症患者住院的高钙血症的治疗结果","authors":"Tasnim Quran, Nour Maraqa, Joud Aqarbeh, Renad Abu-Khader, Ayah Habeeb, Nour Faqeer","doi":"10.1177/10781552251360327","DOIUrl":null,"url":null,"abstract":"<p><p>Limited real-world studies have assessed bisphosphonates (BPs) treatment for hypercalcemia of malignancy (HCM) requiring hospital admission. We aimed to evaluate the response to BPs in terms of rate, timing and 30-day readmission. This retrospective study included adult cancer patients admitted to the hospital with hypercalcemia from January 2019 to August 2023. Medical records were reviewed to collect baseline characteristics and treatment outcomes of HCM, including complete remission (CR), defined as corrected serum calcium (CSC) normalization to 10.8 mg/dl or below, partial response (PR), defined as CSC trending down but not reaching 10.8 upon discharge, and readmission due to hypercalcemia within one month. During the study period, 505 patients were included, with a mean age of 58.2 years (± 12.5 SD); 52.3% were male, predominant cancers were breast 26.1% and lung 16.0%, with 53.9% having bone metastasis. Severe, moderate, and mild hypercalcemia were observed in 30.5%, 46.9%, and 22.6% patients, respectively. Zoledronic acid and pamidronate were administered to 75.4% and 24.6% patients, respectively. CR was achieved in 73.5% of patients, while 19.4% showed PR, and 2.6% had no response. Zoledronic acid led to faster CSC normalization (2.6 days ± 1.5 SD) compared to pamidronate (3.9 days ± 2.4 SD) (P = 0.001). Additionally, 13.7% of patients required readmission due to hypercalcemia, with a significantly lower rate associated with zoledronic acid compared to pamidronate (P = 0.042). While BPs were effective in achieving CR in most patients, a remarkable fraction required readmission, highlighting the need for additional research to identify factors predisposing patients to recurrent hypercalcemia.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552251360327"},"PeriodicalIF":0.9000,"publicationDate":"2025-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Treatment outcomes of hypercalcemia that resulting in hospital admission in cancer patients treated with bisphosphonates in real-world setting.\",\"authors\":\"Tasnim Quran, Nour Maraqa, Joud Aqarbeh, Renad Abu-Khader, Ayah Habeeb, Nour Faqeer\",\"doi\":\"10.1177/10781552251360327\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Limited real-world studies have assessed bisphosphonates (BPs) treatment for hypercalcemia of malignancy (HCM) requiring hospital admission. We aimed to evaluate the response to BPs in terms of rate, timing and 30-day readmission. This retrospective study included adult cancer patients admitted to the hospital with hypercalcemia from January 2019 to August 2023. Medical records were reviewed to collect baseline characteristics and treatment outcomes of HCM, including complete remission (CR), defined as corrected serum calcium (CSC) normalization to 10.8 mg/dl or below, partial response (PR), defined as CSC trending down but not reaching 10.8 upon discharge, and readmission due to hypercalcemia within one month. During the study period, 505 patients were included, with a mean age of 58.2 years (± 12.5 SD); 52.3% were male, predominant cancers were breast 26.1% and lung 16.0%, with 53.9% having bone metastasis. Severe, moderate, and mild hypercalcemia were observed in 30.5%, 46.9%, and 22.6% patients, respectively. Zoledronic acid and pamidronate were administered to 75.4% and 24.6% patients, respectively. CR was achieved in 73.5% of patients, while 19.4% showed PR, and 2.6% had no response. Zoledronic acid led to faster CSC normalization (2.6 days ± 1.5 SD) compared to pamidronate (3.9 days ± 2.4 SD) (P = 0.001). Additionally, 13.7% of patients required readmission due to hypercalcemia, with a significantly lower rate associated with zoledronic acid compared to pamidronate (P = 0.042). While BPs were effective in achieving CR in most patients, a remarkable fraction required readmission, highlighting the need for additional research to identify factors predisposing patients to recurrent hypercalcemia.</p>\",\"PeriodicalId\":16637,\"journal\":{\"name\":\"Journal of Oncology Pharmacy Practice\",\"volume\":\" \",\"pages\":\"10781552251360327\"},\"PeriodicalIF\":0.9000,\"publicationDate\":\"2025-07-17\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Oncology Pharmacy Practice\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1177/10781552251360327\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Oncology Pharmacy Practice","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/10781552251360327","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

有限的现实世界研究评估了双膦酸盐(bp)治疗需要住院的恶性肿瘤高钙血症(HCM)。我们的目的是在发生率、时间和30天再入院率方面评估对bp的反应。这项回顾性研究纳入了2019年1月至2023年8月因高钙血症入院的成年癌症患者。回顾医疗记录以收集HCM的基线特征和治疗结果,包括完全缓解(CR),定义为校正血清钙(CSC)正常化至10.8 mg/dl或以下,部分缓解(PR),定义为CSC呈下降趋势但在出院时未达到10.8,以及在一个月内因高钙血症而再次入院。研究期间共纳入505例患者,平均年龄58.2岁(±12.5 SD);男性占52.3%,乳腺癌占26.1%,肺癌占16.0%,骨转移占53.9%。重度、中度和轻度高钙血症分别占30.5%、46.9%和22.6%。服用唑来膦酸和帕米膦酸的患者分别为75.4%和24.6%。73.5%的患者达到CR, 19.4%的患者达到PR, 2.6%的患者无反应。唑来膦酸比帕米膦酸(3.9天±2.4 SD)更快地促进CSC正常化(2.6天±1.5 SD) (P = 0.001)。此外,13.7%的患者因高钙血症而需要再次入院,与帕米膦酸相比,唑来膦酸的发生率显着降低(P = 0.042)。虽然bp在大多数患者中有效实现CR,但有相当一部分患者需要再次入院,这突出了需要进一步研究以确定患者复发性高钙血症的易感性因素。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Treatment outcomes of hypercalcemia that resulting in hospital admission in cancer patients treated with bisphosphonates in real-world setting.

Limited real-world studies have assessed bisphosphonates (BPs) treatment for hypercalcemia of malignancy (HCM) requiring hospital admission. We aimed to evaluate the response to BPs in terms of rate, timing and 30-day readmission. This retrospective study included adult cancer patients admitted to the hospital with hypercalcemia from January 2019 to August 2023. Medical records were reviewed to collect baseline characteristics and treatment outcomes of HCM, including complete remission (CR), defined as corrected serum calcium (CSC) normalization to 10.8 mg/dl or below, partial response (PR), defined as CSC trending down but not reaching 10.8 upon discharge, and readmission due to hypercalcemia within one month. During the study period, 505 patients were included, with a mean age of 58.2 years (± 12.5 SD); 52.3% were male, predominant cancers were breast 26.1% and lung 16.0%, with 53.9% having bone metastasis. Severe, moderate, and mild hypercalcemia were observed in 30.5%, 46.9%, and 22.6% patients, respectively. Zoledronic acid and pamidronate were administered to 75.4% and 24.6% patients, respectively. CR was achieved in 73.5% of patients, while 19.4% showed PR, and 2.6% had no response. Zoledronic acid led to faster CSC normalization (2.6 days ± 1.5 SD) compared to pamidronate (3.9 days ± 2.4 SD) (P = 0.001). Additionally, 13.7% of patients required readmission due to hypercalcemia, with a significantly lower rate associated with zoledronic acid compared to pamidronate (P = 0.042). While BPs were effective in achieving CR in most patients, a remarkable fraction required readmission, highlighting the need for additional research to identify factors predisposing patients to recurrent hypercalcemia.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
2.70
自引率
7.70%
发文量
276
期刊介绍: Journal of Oncology Pharmacy Practice is a peer-reviewed scholarly journal dedicated to educating health professionals about providing pharmaceutical care to patients with cancer. It is the official publication of the International Society for Oncology Pharmacy Practitioners (ISOPP). Publishing pertinent case reports and consensus guidelines...
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信